Skip to main navigation Skip to search Skip to main content

Correction: AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: Study protocol for a phase 3 randomised controlled non-inferiority trial

  • David S. Lawrence
  • , Nabila Youssouf
  • , Síle F. Molloy
  • , Alexandre Alanio
  • , Melanie Alufandika
  • , David R. Boulware
  • , Timothée Boyer-Chammard
  • , Tao Chen
  • , Francoise Dromer
  • , Admire Hlupeni
  • , William Hope
  • , Mina C. Hosseinipour
  • , Cecilia Kanyama
  • , Oliver Lortholary
  • , Angela Loyse
  • , David B. Meya
  • , Mosepele Mosepele
  • , Conrad Muzoora
  • , Henry Mwandumba
  • , Chiratidzo E. Ndhlovu
  • Louis Niessen, Charlotte Schutz, Katharine E. Stott, Duolao Wang, David Lalloo, Graeme Meintjes, Shabbar Jaffar, Thomas S. Harrison, Joseph N. Jarvis
  • London School of Hygiene and Tropical Medicine
  • Botswana-Harvard AIDS Institute Partnership
  • City St George's, University of London
  • Institut Pasteur Paris
  • Malawi-Liverpool-Wellcome Trust Clinical Research Programme
  • Makerere University
  • University of Minnesota Twin Cities
  • University of Zimbabwe
  • University of Liverpool
  • University of North Carolina at Chapel Hill
  • University of Botswana
  • University of Cape Town

Research output: Other contribution

2 Citations (Scopus)

Abstract

Following publication of the original article [1], we have been notified that one of the author names was listed incorrectly. Both incorrect and correct author names are presented below. The original publication has been corrected. Originally published name: Sile L F Molloy Correct name: Sile F Molloy.
Original languageEnglish
Edition1
Volume20
DOIs
Publication statusPublished - 14 Jan 2019

Publication series

NameTrials
PublisherBioMed Central Ltd
ISSN (Print)1745-6215

Fingerprint

Dive into the research topics of 'Correction: AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: Study protocol for a phase 3 randomised controlled non-inferiority trial'. Together they form a unique fingerprint.

Cite this